ASSOCIATION FOR ACCESSIBLE MEDICINES lobbying for ASSOCIATION FOR ACCESSIBLE MEDICINES

Filing 1st Quarter - Report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 16, 2025

Expenses

$650,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 8

Centers For Medicare and Medicaid Services (CMS)
Federal Trade Commission (FTC)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Natl Economic Council (NEC)
SENATE
U.S. Trade Representative (USTR)
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 8

HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1302
Increasing Transparency in Generic Drug Applications Act
HR 1396
PILLS Act
HR 1051
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application subm…
S 1041
Affordable Prescriptions for Patients Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 43
Skinny Labels, Big Savings Act
S 1040
Drug Competition Enhancement Act

Lobbying activity 4

Pharmacy

Prescription Drug Costs. H.R.1843 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: A bill to provide for increased transparency in generic drug applications. H.R.1396: To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes. Drug Shortages. Biosimilar Interchangeability. H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. E-Labeling.

Medicare/Medicaid

Medicare Part D Reform. H.R._/S._: Ensuring Access to Lower-Cost Medicines for Seniors Act. H.R._/S._: Increasing Access to Biosimilars Act. Medicaid Rebate Penalty.

Copyright/Patent/Trademark

H.R._/S._: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R._/S._: Patent Eligibility Restoration Act. H.R._/S._: To address patent thickets. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. S._: A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. S.43: Skinny Labels, Big Savings Act. S.1040: Drug Competition Enhancement Act.

Trade (domestic/foreign)

General Trade Issues. Drug Supply Chain. Country of Origin Labeling. Tariffs on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars.